How a gut oxygen sensor boosts natural GLP-1 and controls blood sugar
Role of Hypoxia-inducible factor-2a in L-cell nutrient sensing and metabolic homeostasis
Looks at whether an oxygen-sensing protein in the gut helps meals trigger GLP-1 release to improve blood sugar control for people with type 2 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11333263 on NIH RePORTER |
What this research studies
Researchers will use mouse models, intestinal cell experiments, and molecular analyses to learn how HIF-2α in gut L-cells responds to nutrients and controls GLP-1 secretion. They will study how HIF-2α changes expression of the lipid sensor GPR40 and how the metabolite α-ketoglutarate contributes to nutrient signaling. Experiments include genetic disruption and short-term inhibition of HIF-2α, tests of lipid-stimulated GLP-1 release, and glucose tolerance measurements in animals. The aim is to identify mechanisms that could be targeted to boost the body’s own GLP-1 without the gastrointestinal side effects seen with some current GLP-1 drugs.
Who could benefit from this research
Good fit: Adults with type 2 diabetes who want better blood sugar control or alternatives to existing GLP-1–based therapies would be the most relevant patients for future clinical work from this project.
Not a fit: People without type 2 diabetes or those whose diabetes is already well controlled and not seeking GLP-1–based options are unlikely to receive direct benefit from this work.
Why it matters
Potential benefit: Could point to new treatments that increase your own GLP-1 release to lower blood sugar while causing fewer intestinal side effects than current GLP-1 drugs.
How similar studies have performed: GLP-1–based drugs reliably lower blood sugar but often cause GI side effects, and targeting L-cell secretion through HIF-2α is a novel approach with promising preclinical (mouse) data but not yet tested in humans.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Ramakrishnan, Sadeesh Kumar — University of Pittsburgh at Pittsburgh
- Study coordinator: Ramakrishnan, Sadeesh Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.